New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
05:47 EDTSTJSt. Jude Medical announces preliminary results from EnligHTN III study
St. Jude Medical announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. Results from the EnligHTN I, II and III trials presented during EuroPCR add to the growing body of clinical evidence supporting the benefits of EnligHTN renal denervation technologies.
News For STJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:34 EDTSTJEnteroMedics names Brad Hancock Chief Commercial Officer
Subscribe for More Information
October 27, 2014
08:04 EDTSTJSt. Jude Medical receives FDA approval of Tacticath Quartz catheter
Subscribe for More Information
October 22, 2014
07:21 EDTSTJU.S. DHS investigates medical gear for potential cyber defects, Reuters says
Subscribe for More Information
October 20, 2014
07:12 EDTSTJCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use